

## Claims

1. Use of 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one or a physiologically acceptable salt thereof as an active ingredient for the manufacture of a medicament for the treatment of epilepsy in dogs.  
5
2. The use of claim 1 wherein the medicament is for oral administration.
3. The use of claim 1 wherein the medicament is administered 1-5 times daily.
4. The use of claim 1 wherein the daily dose of the active ingredient is from 1 to 200 mg/kg.
- 10 5. The use of any one of claims 1-4 wherein the active ingredient is co-administered with at least one further active ingredient.
6. The use of claim 5 wherein the further active ingredient is selected from phenobarbital, primidone and potassium bromide.
- 15 7. The use of any one of claims 1-6 wherein the epilepsy is idiopathic or symptomatic epilepsy.
8. The use of any one of claims 1-7 for the treatment of newly diagnosed epilepsy.
9. The use of any of claims 1-7 for the treatment of drug-resistant epilepsy.
10. Use of 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one or a physiologically acceptable salt thereof as an active ingredient for the manufacture of a medicament for the treatment of behavioural abnormalities in dogs.  
20
11. The use of claim 10 for the treatment of anxiety.